A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination with Pembrolizumab inPatients With Advanced or Metastatic Hepatocellular Carcinoma
Contact:
NCT Number:
Protocol:
AAAV5831
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to test the safety of an investigational drug called ALN-BCAT, and find out what effects, if any, ALN-BCAT has on people with your type of liver cancer. The effects being studied include: • The frequency and severity of side effects (to determine if the drug is safe) • Whether ALN-BCAT may make tumors smaller • How ALN-BCAT may affect the genes and proteins in your cancer cells • How your body processes ALN-BCAT
Are you Eligible? (Inclusion Criteria)
- Age 18 years or older - Patient able to understand and willing and able to comply with requirements provided in consent form - Patients must have unresectable locally advanced or metastatic HCC
Specialty Area(s)
Liver Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
